SG11201407309XA - Compositions and methods for the treatment of epilepsy - Google Patents
Compositions and methods for the treatment of epilepsyInfo
- Publication number
- SG11201407309XA SG11201407309XA SG11201407309XA SG11201407309XA SG11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA
- Authority
- SG
- Singapore
- Prior art keywords
- disorder
- international
- formula
- epilepsy
- seizures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/167986 A2 (51) International Patent Classification: Not classified (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/050740 29 January 2013 (29.01.2013) English English (30) Priority Data: 1791/CHE/2012 8 May 2012 (08.05.2012) IN (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (72) Inventor: KANDULA, Mahesh; Door No. 11-61, East Godavari Dist, Samalkot Mandal, Andhra Pradesh, G.medapadu 533434 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ 00 as i-H cn i-H o CJ o & (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY (57) Abstract: The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II); and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such composi - tions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder, partial seizures, adjunctive therapy for partial, myoclonic, tonic-clonic seizures and schizophrenia, neuropathic pain, seizures, Tourette syn drome, Alzheimer's disease, autism, bipolar disorder and anxiety disorder, bipolar disorder, mania, phantom limb syndrome, com - plex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotoaia, intermittent explosive disorder, borderline person ality disorder, myotonia congenita and post-traumatic stress disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1791CH2012 | 2012-05-08 | ||
PCT/IB2013/050740 WO2013167986A2 (en) | 2012-05-08 | 2013-01-29 | Compositions and methods for the treatment of epilepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407309XA true SG11201407309XA (en) | 2014-12-30 |
Family
ID=54187089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407309XA SG11201407309XA (en) | 2012-05-08 | 2013-01-29 | Compositions and methods for the treatment of epilepsy |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2846795A2 (en) |
JP (1) | JP2015526385A (en) |
AU (1) | AU2013257707A1 (en) |
CA (1) | CA2873016A1 (en) |
SG (1) | SG11201407309XA (en) |
WO (1) | WO2013167986A2 (en) |
ZA (1) | ZA201408058B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104379589A (en) * | 2012-05-07 | 2015-02-25 | 塞利克斯比奥私人有限公司 | Prodrugs of anti-platelet agents |
CA2873018A1 (en) * | 2012-07-03 | 2014-01-09 | Cellixbio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2015184542A1 (en) * | 2014-06-02 | 2015-12-10 | Ketogen Inc. | Compounds for the treatment of seizures and other central nervous system disorders and conditions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL183678B1 (en) * | 1995-05-05 | 2002-06-28 | Novo Nordisk As | Pharmaceutic agent containing thiagabine chlorhydride and method of obtaining same |
WO2006062980A2 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising tiagabine |
US8338621B2 (en) * | 2005-12-21 | 2012-12-25 | Ucb S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
WO2010132693A2 (en) * | 2009-05-13 | 2010-11-18 | Nektar Therapeutics | Oligomer-containing pyrrolidine compounds |
-
2013
- 2013-01-29 JP JP2015510893A patent/JP2015526385A/en active Pending
- 2013-01-29 SG SG11201407309XA patent/SG11201407309XA/en unknown
- 2013-01-29 EP EP13787779.1A patent/EP2846795A2/en not_active Withdrawn
- 2013-01-29 CA CA2873016A patent/CA2873016A1/en not_active Abandoned
- 2013-01-29 WO PCT/IB2013/050740 patent/WO2013167986A2/en active Application Filing
- 2013-01-29 AU AU2013257707A patent/AU2013257707A1/en not_active Abandoned
-
2014
- 2014-11-04 ZA ZA2014/08058A patent/ZA201408058B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2873016A1 (en) | 2013-11-14 |
AU2013257707A1 (en) | 2014-11-27 |
WO2013167986A3 (en) | 2015-06-18 |
EP2846795A2 (en) | 2015-03-18 |
JP2015526385A (en) | 2015-09-10 |
ZA201408058B (en) | 2016-03-30 |
WO2013167986A2 (en) | 2013-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
SG11201407326XA (en) | Compositions and methods for treatment of mucositis | |
SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201407596TA (en) | Conjugation reagents | |
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
SG11201408261UA (en) | Syringe | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201407303SA (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
SG11201407317SA (en) | Compositions and methods for suppression of carbonic anhydrase activity | |
SG11201407934UA (en) | Camsylate salt |